Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
| Revenue (Most Recent Fiscal Year) | $164.07M |
| Net Income (Most Recent Fiscal Year) | $-372.18M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.87 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -178.02% |
| Net Margin (Trailing 12 Months) | -176.49% |
| Return on Equity (Trailing 12 Months) | -49.71% |
| Return on Assets (Trailing 12 Months) | -39.18% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.18 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.64 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 3.63 |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.36 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.28 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.24 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 333.93M |
| Free Float | 293.53M |
| Market Capitalization | $611.10M |
| Average Volume (Last 20 Days) | 19.31M |
| Beta (Past 60 Months) | 1.06 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 12.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 77.03% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |